Study Nearly Doubles Known Cancer-Linked Mutational Signatures
Analyzing the whole genome sequences of more than 18,000 tumors, researchers catalog nearly 60 new patterns of mutations that could inform cancer treatment.
Study Nearly Doubles Known Cancer-Linked Mutational Signatures
Study Nearly Doubles Known Cancer-Linked Mutational Signatures
Analyzing the whole genome sequences of more than 18,000 tumors, researchers catalog nearly 60 new patterns of mutations that could inform cancer treatment.
Analyzing the whole genome sequences of more than 18,000 tumors, researchers catalog nearly 60 new patterns of mutations that could inform cancer treatment.
In vitro and mouse experiments show how cancer cells forced through tiny pores—mimicking the physical experience of metastasis—resisted programmed cell death and avoided detection by the immune cells that would normally kill them.
From diagnosis to tracking treatment responses, bacteria and other microbes in the blood, gut, and tumors of cancer patients may provide helpful hints for improving their care.
From a Nobel prize and photosynthesis-powered brains to neurodegeneration research and controversy over a new Alzheimer’s drug, a look back at some of the biggest brain-related developments of the year.
This year revealed just how much scientists have learned about the disease, from how animals become naturally cancer-resistant to how tumor cells harness extracellular DNA to develop rapid drug resistance.
Researchers involved in an eight-year project to reproduce the findings of more than 50 high-impact papers struggled to get enough information to even carry out most of the experiments.
The long noncoding RNA MINCR, implicated in ALS and Alzheimer’s disease as well as several types of cancer, appears to function differently when present at high versus low levels.